drugset / Trial / NCT00375596

A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

NCT00375596

Phase 2 Withdrawn Bausch & Lomb Incorporated
Parallel-group

Summary

This study will evaluate the safety and efficacy of a new allergy medication

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketotifen Small molecule

Indications